α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease - Benskey - 2016 - Journal of Neurochemistry - Wiley Online Library

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

α-Synuclein Aggregation in Treatment of Parkinson's Disease

Novel and rapid device opens new doors for Pa

Models of α-synuclein aggregation in Parkinson's disease, Acta Neuropathologica Communications

Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease, Molecular Brain

Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Current hypotheses for the involvement of a-synuclein in Parkinson's

Parkinsons Disease - Neurobiology and Aetiology - Neurotorium

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome